Explore real-world BPC-157/TB-500 blend dosage trends, reconstitution volumes, and vial size preferences from WPA peptide calculator sessions.
The BPC-157/TB-500 blend combines two of the most researched healing peptides into a single reconstitution protocol. This data shows the combined dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly use when mixing this synergistic peptide blend.
The BPC-157/TB-500 blend is a deliberate two-peptide pairing that brings together the two most-researched healing peptides in the modern marketplace. The rationale traces to two separate preclinical bodies of work that converged in the early 2010s. BPC-157 — the Body Protection Compound pentadecapeptide — comes from the Sikiric et al. program at the University of Zagreb, which produced more than 200 published rodent and dog studies on its effects in gastric ulcer protection, tendon-to-bone healing, ligament repair, and accelerated wound closure. TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4, the actin-sequestering peptide first characterized in the Goldstein et al.
This blend pairs BPC-157 and TB-500, two tissue-repair peptides, and is one of the most-sourced research blends for soft-tissue and recovery protocols. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
BPC-157 acts on the VEGF–NO pathway and modulates growth-hormone-receptor expression in fibroblasts, while TB-500 sequesters G-actin and promotes endothelial-cell migration, angiogenesis, and stem-cell mobilization. The two molecules engage distinct repair mechanisms, which is the rationale behind their combination in research protocols.
No published trials evaluate the fixed-ratio combination. Individual evidence draws from the Sikiric group on BPC-157 (>200 animal studies) and the Goldstein/RegeneRx work on thymosin beta-4 in dermal wound healing, dry-eye disease, and post-MI cardiac repair. Both molecules appear on the FDA 503A "do not compound" interest list.
BPC-157/TB-500 Blend has a reported half-life of ~2 days (TB-500-driven), and the dose intervals researchers model most often fall around weekly (or split into 2 doses). TB-500 carries the buildup story here; BPC-157 clears quickly and BPC tone depends on dosing frequency. Splitting the weekly dose into two injections keeps both components more stable. BPC-157/TB-500 Blend is a blend of BPC-157 and TB-500, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Recovery Peptides on WPA.
4,020 BPC-157/TB-500 Blend reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (1,257 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (2,066 sessions). The most common dosing frequency is daily (7x/week) (408 logged protocols), followed by once weekly (206).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.